TNF antagonist safety in rheumatoid arthritis: updated evidence from observational registries.
Although the efficacy of tumor necrosis factor (TNF) antagonists for the treatment of rheumatoid arthritis (RA) has been established in randomized controlled trials (RCTs), safety concerns have emerged, particularly with regard to risk of infection, malignancy, and cardiovascular (CV) outcomes. Because of the shorter duration and limited number of patients enrolled in RCTs, evidence regarding the risk of rare adverse outcomes is frequently inconclusive. Longterm observational studies, as well as RCT meta-analyses, provide additional safety data. This review discusses the emerging evidence from observational registries on the risk of infection, malignancy, and CV outcomes associated with TNF antagonists.
Nasir
Adeel
A
Division of Rheumatology, NYU Hospital for Joint Diseases, and New York University School of Medicine, New York, NY 10003, USA.
Greenberg
Jeffrey D
JD
D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000150:complications / Q000188:drug therapy*; D002318:Cardiovascular Diseases / Q000209:etiology; D006801:Humans; D008223:Lymphoma / Q000209:etiology; D016032:Randomized Controlled Trials as Topic; D012042:Registries; D012307:Risk Factors; D000079424:Tumor Necrosis Factor Inhibitors
D018501:Antirheumatic Agents; D000079424:Tumor Necrosis Factor Inhibitors